Cel-Sci Corporation (CVM)
|Net Income (ttm)||-35.13M|
|Trading Day||June 21|
|Day's Range||22.10 - 22.80|
|52-Week Range||10.76 - 40.91|
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces the closing of $31.7 million bought deal offering.
CEL-SCI Corporation (NYSE: CVM) has increased the size of its previously announced capital raise offering to 1.4 million shares, up from 1 million shares, at $22.62 per share representing a 5% discount ...
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million.
VIENNA, Va.--(BUSINESS WIRE)-- #CVM--CEL-SCI Announces Bought Deal Offering
Big news is coming for CEL-SCI, and we don't know which way the stock will move.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports second quarter fiscal 2021 financial results.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation reports first quarter fiscal 2021 financial results.
Investors are betting that these three stocks could turn them into millionaires in incredibly short periods of time. Will they succeed?
CVM stock is on the move after Cel-Sci CEO Geert Kersten joined the battle against GME stock short-sellers. Here's what to know.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation issues letter to shareholders.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI reports fiscal 2020 financial results and clinical & corporate developments.
Data lock has been announced, and top line data is to be expected within a few weeks. Trial duration hints towards longer survival than Standard of Care.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI announces the closing of its $14.65 million bought deal.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Bought Deal Offering.
Data is Locked. NWBO's Data Lock announcement boosted their Market Cap to nearly $2B.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Update on Phase 3 Cancer Trial Results.
CEL-SCI's LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI's LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at H.C.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation reports third quarter fiscal 2020 financial results.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment.
CEL-SCI: What's Next
Cel-Sci: A Zombie Biotech Company
CEL-SCI's Multikine: Can It Really Be This Good?
Who has the upper ground in a war between investors and short-sellers about whether a biotech's clinical trial for treating head and neck cancer can succeed?
Cel-Sci: It's All Happening
CEL-SCI announced that it is developing an immunotherapy for COVID-19 based on its LEAPS peptide technology.
CEL-SCI: LEAPS & COVID-19
Cel-Sci: The Upside Is Still There
Cel-Sci: Little Known Drug Validates Multikine's Investigation Goals
CEL-SCI: Food For Thought Before The Big Day
CEL-SCI: The Homestretch
Bearish CEL-SCI Article Ignored Scientific Evidence And Misinterpreted Multikine's Clinical Trial Design
The mechanism of action for cytokines in helping the immune system respond to malignant growth in the head and neck has been well documented by medical research.
Multikine's Phase 3 trial accounts for the short half-lives of cytokines post administration, which may lead to significant improvements in its clinical profile compared to Phase 2.
The world's largest head and neck cancer study should have ended in late 2018 but patients appear to be living longer.
The world's largest head and neck cancer study should have ended in late 2018, but patients appear to be living longer.
Multikine is a cytokine-based immunotherapeutic compound intended to cure Head and Neck Squamous-Cell Carcinoma, which is currently being tested in a large Phase III trial.
These stocks were huge winners last week. But can their momentum continue?
May 8, 2019 Cel-Sci Corporation released a letter to investors indicating the Phase 3 Multikine trial had not yet reached its endpoint of 298 endpoints (deaths) in the two arms.
CEL-SCI's Multikine Phase III Trial in Squamous Cell Cancer of Head and Neck Continues as the End-Point Has Still Not Yet Been Reached.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and ... [Read more...]
|IPO Date |
Jan 1, 1987
|Stock Exchange |
|Ticker Symbol |
In 2020, CVM's revenue was $597,427, an increase of 11.51% compared to the previous year's $535,776. Losses were -$30.28 million, 36.8% more than in 2019.
The average 12-month stock price forecast for CVM is 19.00, which is a decrease of -15.03% from the latest price.